Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on August 1, 2019. The company is a biopharmaceutical firm focused on rare diseases, with its principal executive offices located in Novato, California. The report addresses a specific corporate event occurring on the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The application is for the company's investigational drug UX007 (triheptanoin), intended for the treatment of long-chain fatty acid oxidation disorders.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the NDA submission. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the inherent regulatory review process associated with the NDA. No unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the status of the NDA for UX007 (triheptanoin) with the FDA.
- Review the full text of the press release filed as Exhibit 99.1 for additional details on the drug's development.
- Monitor future filings for FDA responses, potential approval timelines, or clinical trial updates.
- Check subsequent quarterly reports (10-Q) or annual reports (10-K) for financial impact related to this development milestone.